Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop(University of Copenhagen), W. Timothy Garvey(University of Alabama at Birmingham), Thomas Holst‐Hansen(Novo Nordisk (Denmark)), Domenica Rubino(Washington Center for Weight Management and Research), Peter Nørkjær Laursen(Novo Nordisk (Denmark)), Vanita R. Aroda(Brigham and Women's Hospital), Ruben D do Vale(Novo Nordisk (Denmark)), Julio Rosenstock(Dallas Diabetes Research Center)
Cited by 377
Related Papers
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
|JAMA|2021|1.2k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
Recovery of gut microbiota of healthy adults following antibiotic exposure
|Nature Microbiology|2018|871